AN ACTIVE ROLE OF ADAPTOR PROTEINS IN TYROSINE KINASE INHIBITOR RESISTANCE
AN ACTIVE ROLE OF ADAPTOR PROTEINS IN TYROSINE KINASE INHIBITOR RESISTANCE
批准号:
8756983
负责人:
ERIC B. HAURA
金额:
$21.99万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2016-06-30
关键词:
Adaptor Signaling ProteinAddressAffinity ChromatographyBindingBiological AssayCancer cell lineCellsComplexDimerizationDrug resistanceEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErlotinibFutureGoalsGrowth FactorHandIn SituLaboratoriesLigandsLigationMalignant neoplasm of lungMass Spectrum AnalysisMeasurementMeasuresMediatingMedicineModelingMutateOncogenesOutcomePatientsPeptidesPharmaceutical PreparationsPhosphorylationPhosphotyrosinePlayProcessRNA InterferenceReceptor Protein-Tyrosine KinasesReportingResistanceRoleShapesSignal TransductionTestingTherapeutic UsesTyrosineTyrosine Kinase InhibitorTyrosine Phosphorylationadvanced diseasebasecancer cellcell typeimprovedliquid chromatography mass spectrometrymutantneoplastic cellnovelnovel therapeutic interventionprotein complexpublic health relevancereceptorresponsesuccesstumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to define an active role of adaptor proteins in mediating resistance to receptor tyrosine kinase (RTK) inhibitors. In the field
of lung cancer therapeutics, use of tyrosine kinase inhibitors (TKI) directed against mutant forms of EGFR or EML4-ALK rearranged lung cancers has made major improvements in patient outcome with advanced disease. However, intrinsic or acquired drug resistance remains a persistent obstacle towards a cure. Growth factor ligands secreted in the tumor microenvironment can negate the effects of TKI across multiple tumor cell types driven by mutant oncogenes. We propose that adaptor proteins involved in RTK signaling are playing an active role in this process. We hypothesize that adaptors, displaced from driver RTK by TKI, shape co-expressed RTK signaling and influence the effects of microenvironmental ligands that drive resistance. Our model, to be tested in this project, consists of adaptor proteins being relocalized from the targeted driver RTK to other co-expressed RTK. This switching of adaptors to the co- expressed RTK enables priming phosphorylation mediated by direct binding of the adaptor and dimerization of two RTK molecules. This allows for full RTK activation in the presence of minute amounts of growth factor ligands. In our laboratory, using various phosphoproteomic approaches, including direct measurements of phosphotyrosine peptide abundance using mass spectrometry, we have consistently identified increased abundance of RTK tyrosine phosphorylation in co-expressed RTK following treatment of cells with TKI directed against the driver oncogene. Our results suggest that priming phosphorylation following TKI treatment of co- expressed RTK can be related to ability of some growth factors to drive TKI resistance. We will test this model using mass spectrometry and proximity ligation assays to quantitatively and qualitatively examine adaptor and RTK complexes in cells following TKI treatment. Specific aim 1 will characterize the fate of adaptor proteins and changes in protein complexes in co-expressed RTK following TKI. Specific aim 2 will characterize how RTK:adaptor pairing relates to growth factor ligand rescue. Specific aim 3 will characterize the role of adaptor proteins in priming tyrosine phosphorylation of co-expressed RTK. Success in this project will identify an active role in adaptor proteins in shaping TKI responses and can in the future yield predictive markers identifying tumors rapidly adapting to TKI through growth factor ligand rescue. The hypothesis is novel and therefore important to be tested. Complex approaches to measuring protein complexes are in hand further increasing the chances of success.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach
-
批准号:10722113
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2023
-
负责人:ERIC B. HAURA
-
依托单位:
Targeting bidirectional signaling in lung stroma and cancer cells
-
批准号:10227777
-
项目类别:
-
资助金额:$47.82万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Precision lung cancer therapy design through multiplexed adapter measurement
-
批准号:10246394
-
项目类别:
-
资助金额:$45.94万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Precision lung cancer therapy design through multiplexed adapter measurement
-
批准号:9759874
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Precision lung cancer therapy design through multiplexed adapter measurement
-
批准号:9388399
-
项目类别:
-
资助金额:$44.62万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Applying Chemical Biology to Target Deubiquitinating Enzymes in Lung Cancer
-
批准号:9375662
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Targeting bidirectional signaling in lung stroma and cancer cells
-
批准号:9982983
-
项目类别:
-
资助金额:$50.68万
-
财政年份:2017
-
负责人:ERIC B. HAURA
-
依托单位:
Validation of EGFR Protein Complexes as Molecular Diagnostics
-
批准号:10221627
-
项目类别:
-
资助金额:$30.87万
-
财政年份:2016
-
负责人:ERIC B. HAURA
-
依托单位:
Validation of EGFR Protein Complexes as Molecular Diagnostics
-
批准号:10436863
-
项目类别:
-
资助金额:$13.86万
-
财政年份:2016
-
负责人:ERIC B. HAURA
-
依托单位:
Validation of EGFR Protein Complexes as Molecular Diagnostics
-
批准号:9927868
-
项目类别:
-
资助金额:$33.12万
-
财政年份:2016
-
负责人:ERIC B. HAURA
-
依托单位:
ACTIVITY-BASED KINASE DISCOVERY IN SMALL CELL LUNG CANCER
-
批准号:8635989
-
项目类别:
-
资助金额:$18.29万
-
财政年份:2013
-
负责人:ERIC B. HAURA
-
依托单位:
ACTIVITY-BASED KINASE DISCOVERY IN SMALL CELL LUNG CANCER
-
批准号:8511210
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2013
-
负责人:ERIC B. HAURA
-
依托单位:
PROTEIN PROTEIN INTERACTIONS AS BIOMARKERS
-
批准号:8183229
-
项目类别:
-
资助金额:$21.79万
-
财政年份:2011
-
负责人:ERIC B. HAURA
-
依托单位:
PROTEIN PROTEIN INTERACTIONS AS BIOMARKERS
-
批准号:8325680
-
项目类别:
-
资助金额:$18.16万
-
财政年份:2011
-
负责人:ERIC B. HAURA
-
依托单位:
P3 - Antitumor Mechanisms of SRC Inhibitors in Lung Cancer
-
批准号:8118130
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2010
-
负责人:ERIC B. HAURA
-
依托单位:
CDP - Career Development Program
-
批准号:8118134
-
项目类别:
-
资助金额:$9.65万
-
财政年份:2010
-
负责人:ERIC B. HAURA
-
依托单位:
SPORE in Lung Cancer
-
批准号:7883902
-
项目类别:
-
资助金额:$15.86万
-
财政年份:2009
-
负责人:ERIC B. HAURA
-
依托单位:
SPORE in Lung Cancer
-
批准号:7919122
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2009
-
负责人:ERIC B. HAURA
-
依托单位:
A novel molecular diagnostic approach to classify lung cancers and predict respon
-
批准号:7836572
-
项目类别:
-
资助金额:$49.41万
-
财政年份:2009
-
负责人:ERIC B. HAURA
-
依托单位:
A novel molecular diagnostic approach to classify lung cancers and predict respon
-
批准号:7943964
-
项目类别:
-
资助金额:$48.91万
-
财政年份:2009
-
负责人:ERIC B. HAURA
-
依托单位:
海外基金